GlassScriptPhysician profile
Kara Mineo
NPI 1932981487
$1,805.78
in general payments reported to CMS, 2019-2025
15 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,302 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.79 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $574.13 | 2024-2025 | |
| Incyte Corporation | $280.24 | 2024-2025 | Opzelura |
| Dermavant Sciences, INC. | $192.19 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $107.87 | 2024 | Zoryve |
| Galderma Laboratories, L.P. | $98.78 | 2024-2025 | Dysport |
| Janssen Biotech, INC. | $93.64 | 2024 | Tremfya |
| Revance Therapeutics, INC. | $93.63 | 2024 | Daxxify |
| Verrica Pharmaceuticals INC. | $90.87 | 2024-2025 | Ycanth |
| Regeneron Healthcare Solutions, INC. | $70.54 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $62.05 | 2024 | Taltz, Olumiant |
| Pfizer INC. | $47.45 | 2024 | |
| Genzyme Corporation | $31.47 | 2024 | |
| Merz North America, INC. | $23.92 | 2025 | |
| Biofrontera INC. | $20.04 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Sun Pharmaceutical Industries INC. | $18.96 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Mineo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.